SEC Form 4 · accession 0001104659-17-043898
IMMUNOMEDICS INC · IMMU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jul 3, 2017
Accepted (ET)
Jul 6, 2017 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000722830
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $9.02 | Jul 3, 2017 | A | 22,500 | A | Jul 3, 2018 | Jul 3, 2024 | Common Stock, par value $0.01 per share | 22,500 | 22,500 | D |
Remarks
The Investment Manager may be deemed to be a director by deputization of the Issuer by virtue of the fact that Dr. Agahazadeh currently serves on the board of directors of the Issuer.